Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...